First, by reducing chemerin’s pro-inflammatory effects, such therapies could mitigate the inflammatory response following myocardial infarction, which is known to contribute to adverse cardiac remodelling and heart failure and remains a major target of anti-inflammatory therapy [135]. This evidence concerns the gene RARRES2 and heart failure.